AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

How Xero's big Melio buy could double revenue
Markets

How Xero's big Melio buy could double revenue

CEO Sukhinder Singh Cassidy has marked three years at Xero with a chunky new goal.

Heartland reaps benefit of change, reiterates guidance
Finance

Heartland reaps benefit of change, reiterates guidance

Bank looks to sustainable, profitable growth.

Andy Macdonald 13 Nov 2025
Comvita Florenz deal: shareholder voting puts takeover in doubt
Markets

Comvita Florenz deal: shareholder voting puts takeover in doubt

Comvita shareholders can change their vote at a November 14 meeting.

Staff reporters 13 Nov 2025
Blackpearl launches $11.8m ASX placement
Markets

Blackpearl launches $11.8m ASX placement

Software company says investors should jump on its US market opportunity.